CLAIMS

1. A composition comprising SPR720 for use in treating an infection in an adult human patient, said composition to be orally administered to the patient at 500 mg SPR720 once daily for at least 14 days, or 1000 mg SPR720 once daily for at least 14 days, where the infection is a tuberculous infection of a nontuberculous mycobacteria pulmonary disease (NTM-PD).

2. A composition for use according to claim 1, wherein the 500 mg SPR720 is orally administered once daily for at least 28 days.

3. A composition for use according to claim 1, wherein the 1000 mg SPR720 is orally administered once daily for at least 28 days.

4. A composition for use according to any one of claims 1-3, wherein the infection is a tuberculosis infection.

5. A composition for use according to any one of claims 1-3, wherein the infection is a Mycobacterium avium complex (MAC) infection.

6. A composition for use according to claim 5, wherein the MAC infection includes infection with one or both of *M. abscessus* and *M. kansasii.*

7. A composition for use according to any one of claims 1-6, wherein use of the compound is a prophylactic treatment, in a patient known to be at enhanced risk of bacterial infection.

8. A composition for use according to claim 7, wherein the patient is a cystic fibrosis patient.

9. A composition for use according to claim 7, wherein the patient has an underlying condition selected from immunodeficiency, chronic obstructive pulmonary disease (COPD), cavitary or fibo-cavitary lung disease, current or previous treatment with an antitumor necrosis factor agent, neutropenia, a hematologic malignancy, a history of hematopoietic stem cell transplant, a history of solid organ transplant, current treatment with immunosuppressive therapy, current treatment with cancer chemotherapy, current treatment with monoclonal antibodies for autoimmune disease, previous or current *C. difficile* infection, hepatic impairment as evidenced by alanine aminotransferase or aspartate aminotransferase >2 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN, clinical signs of cirrhosis or end-stage hepatic disease (e.g., ascites, hepatic encephalopathy), renal impairment as evidenced by a creatine clearance of < 50 mL/min., and end-stage renal disease requiring hemodialysis or peritoneal dialysis.

10. A composition for use according to any one of the preceding claims, wherein treatment with SPR720 is continued until the patient experiences improvement in at least one of the following symptoms: cough, hemoptysis, fatigue, chest pain, poor appetite, fever, night sweats, and weight loss.

11. A composition for use according to any one of the preceding claims, wherein the patient is also administered an additional agent selected from amikacin, azithromycin, rifampin, rifabutin, ethambutol HCl, clarithromycin, streptomycin, amikacin, or an inhaled steroid.

12. A composition for use according to claim 11, wherein the daily dose of the additional agent is 500 mg to 1000 mg clarithromycin, 10 mg/kg to 20 mg/ kg ethambutol hydrochloride, 250 mg to 500 mg, 100 mg to 1000m rifampin, or 100 mg to 500 mg rifabutin.

13. A composition for use according to claim 1, wherein the NTM-PD is:
(a) nodular bronchiectatic NTM-PD; or(b) fibro-cavitary NTM-PD.

14. A composition for use in treating a patient having a nontuberculous mycobacterial (NTM) infection which is resistant to at least one of amikacin, clarithromycin and fluoroquinolone antibiotics, said composition to be orally administered to the patient at 500 mg SPR720 once daily for at least 14 days or 1000 mg SPR720 once daily for at least 14 days.

15. A composition for use in treating a non-tuberculous mycobacteria (NTM) infection in a patient, said composition comprising:

(i) a once daily oral dosage of SPR720 or a pharmaceutically acceptable salt thereof, the oral dosage of SPR720 comprising 500 mg to 1000 mg SPR720;

(ii) a once daily oral dosage of clarithromycin or a pharmaceutically acceptable salt thereof, the oral dosage of clarithromycin comprising 500 mg to 1000 g clarithromycin; and

(iii) a once daily oral dosage of ethambutol HCl comprising about 15 mg/ kg ethambutol.